

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858

CONSOLIDATED FINANCIAL REPORT
FOR THE YEAR ENDED
30 June 2026

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
DIRECTORS' REPORT

The directors present their report together with the financial report of Global Bionic Optics Limited ("the Company") and its controlled entity ("the Group") for the financial year ended 30 June 2026 and the auditor's report thereon.

Directors

The names of directors in office at any time during or since the end of the financial year are:

Luigi Ghirardello	Company Director Appointed 21 September 2014
John Florent	Company Director & Company Secretary Appointed 3 September 2014
Stephen Diggle	Company Director Appointed 21 September 2014

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

Company Secretary

John Florent was appointed Company Secretary 3 September 2014.

Meetings of Directors

During the financial year 1 meeting of directors was held. Attendance was:

	DIRECTORS' MEETINGS	
	Number eligible to attend	Number Attended
Luigi Ghirardello	1	1
John Florent	1	1
Stephen Diggle	1	1

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
DIRECTORS' REPORT

Principal Activities

The principal activity of the Group during the year to 30 June 2026 has been the commercialisation of advanced imaging products.

There were no significant changes in the nature of the activities of the Group during the year.

Review & Results of Operations

The operating loss of the Group after providing for income tax amounted to \$1,068,368 (2025: loss of \$1,270,122).

The Company holds the patents in the USA and Europe for the Company's unique Biometric Cryptographic Technology.

Dividends

No dividends were paid or recommended during the year.

State of Affairs

In the opinion of the Directors there were no significant changes in the state of affairs of the Group that occurred during the financial year.

After Balance Date Events

No other matter or circumstance has arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in subsequent years.

Future Developments

The Group has commercialised the ZeroBiometrics Technology. The technology is a biometric authentication solution that produces a personalised secure hash code and a private key for identity authentication without the need to retain any biometric template or private cryptographic key. This eliminates any privacy and security risks for digital identity applications across various sectors of fintech, Government ID, e-commerce, healthcare, gaming and other use cases.

Environmental Issues

The Group's operations are not subject to any significant environmental regulation under the law of the Commonwealth and State or Territory.

Options

No options were granted nor shares issued as a result of the exercise of options during the financial year or since the end of the financial year. No unissued shares are subject to options at the date of this report.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
DIRECTORS' REPORT

Proceedings on Behalf of Group

No person has applied for leave of Court to bring proceedings on behalf of the or intervene in any proceedings to which the Group is a part for the purpose of taking responsibility on behalf of the Group for all or part of those proceedings.

The Group was not a party to any such proceedings during the year.

Indemnifying and Insurance of Officers and Auditor

During or since the end of the financial year the Group has not given an indemnity or entered into an agreement to indemnify any person who is or has been an officer or auditor of the Group.

Auditor's Independence Declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set on page 5.

Signed in accordance with a resolution of the Board of Directors.



Luigi Ghirardello



John Florent

Dated this 7th day of September 2026

**AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF
GLOBAL BIONIC OPTICS LIMITED**

I declare that, to the best of my knowledge and belief, in relation to the audit for the financial year ended 30 June 2026 there has been:

- (i) no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation to the audit; and
- (ii) no contraventions of any applicable code of professional conduct in relation to the audit.

Essential Assurance Services Pty Ltd
ABN 51 119 802 229
Authorised Audit Company #305383

A handwritten signature in black ink, appearing to read 'Rhonda Futterleib', with a large, stylized initial 'R'.

Rhonda Futterleib
7th September 2026
22 Pulteney Street, Taree 2430

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2026

		Consolidated Group	
	Note	2026	2025
		\$	\$
Revenue	2	318,225	76,529
Other income	2	-	-
Finance expense	3	(339,340)	(290,421)
Employee expenses		(120,298)	(257,775)
Depreciation & amortisation expense	4	(43,678)	(41,688)
Other expenses		(883,277)	(756,767)
Profit/(loss) before income tax expense/(benefit)		(1,068,368)	(1,270,122)
Income tax (expense)/benefit	5(a)	-	-
Profit/(loss) after income tax expense/(benefit)		(1,068,368)	(1,270,122)
Other comprehensive income		(119,634)	18,719
Total comprehensive income for the year		(1,188,002)	(1,251,402)
Loss for year attributable to:			
Non controlling interest		(284,756)	(338,530)
Owners of the parent		(783,612)	(931,592)
		(1,068,368)	(1,270,122)
Total comprehensive income attributable to:			
Non controlling interest		(296,042)	(311,941)
Owners of the parent		(891,960)	(939,461)
		(1,188,002)	(1,251,402)

The accompanying notes form part of these consolidated financial statements.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2026

	Retained Earnings	Foreign Currency Translation Reserve	Share Capital	Total
	\$	\$	\$	\$
Balance 30 June 2024	(38,533,367)	147,183	31,627,566	(6,758,618)
2025 Profit / (Loss) for year	(1,270,122)	-	-	(1,270,122)
Other Comprehensive income / (loss) for the year	-	18,719	-	18,719
Shares issued during year	-	-	-	-
Balance 30 June 2025	(39,803,489)	165,902	31,627,566	(8,010,021)
2026 Profit / (Loss) for year	(1,068,368)	-	-	(1,068,368)
Other Comprehensive income / (loss) for the year	-	(119,634)	-	(119,634)
Shares issued / bought back during year	-	-	-	-
Balance 30 June 2026	(40,871,857)	46,268	31,627,566	9,198,023

The accompanying notes form part of these consolidated financial statements.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2026

	Note	2026 \$	2025 \$
CURRENT ASSETS			
Cash & cash equivalents	7	65,943	30,132
Trade & other receivables	8	1,020	6,120
Other assets	9	26,248	2,121
TOTAL CURRENT ASSETS		<u>93,211</u>	<u>38,373</u>
NON-CURRENT ASSETS			
Plant and equipment	10	5,594	28,668
Intangible assets	11	35,559	57,499
TOTAL NON-CURRENT ASSETS		<u>41,153</u>	<u>86,167</u>
TOTAL ASSETS		<u>134,364</u>	<u>124,540</u>
 CURRENT LIABILITIES			
Trade and other payables	12	251,752	113,469
Financial liabilities	13	9,080,635	8,021,092
TOTAL CURRENT LIABILITIES		<u>9,332,387</u>	<u>8,134,561</u>
NON-CURRENT LIABILITIES			
TOTAL NON-CURRENT LIABILITIES		<u>-</u>	<u>-</u>
TOTAL LIABILITIES		<u>9,332,387</u>	<u>8,134,561</u>
NET ASSETS		<u>(9,198,023)</u>	<u>(8,010,021)</u>
 EQUITY			
Contributed equity	14	31,627,566	31,627,566
Reserves		46,268	165,902
Retained losses		(38,975,017)	(37,956,231)
Equity attributable to non controlling interest		(1,896,840)	(1,847,258)
TOTAL EQUITY		<u>(9,198,023)</u>	<u>(8,010,021)</u>

The accompanying notes form part of these consolidated financial statements.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2026

	Note	2026 \$	2025 \$
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers/members		323,325	71,429
Payments to suppliers and employees		(889,419)	(1,048,306)
Net GST (remitted to)/received from ATO		-	1,447
Net cash provided by (used in) operating activities	19	(566,094)	(975,430)
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		1,336	(11,642)
Net cash provided by (used in) investing activities		1,336	(11,642)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds/(repayment borrowings)		720,203	988,347
Net cash provided by (used in) financing activities		720,203	988,347
Net increase in cash held		155,445	1,275
Effect of exchange rate changes on cash & cash equivalents		(119,634)	18,719
Cash & cash equivalents at 1 July 2025		30,132	10,138
Cash & cash equivalents at 30 June 2026	7	65,943	30,132

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
CONSOLIDATED ENTITY DISCLOSURE STATEMENT
FOR THE YEAR ENDED 30 June 2026

Name of Entity	Type of Entity	% of Share Capital held	Country of Incorporation	Australian or Foreign Resident	Foreign Tax Jurisdiction of Foreign Residents
ZeroBiometrics Pte Ltd	Company	70	Singapore	Foreign Resident	Singapore

The accompanying notes form part of these consolidated financial statements.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

NOTE 1: MATERIAL ACCOUNTING POLICY INFORMATION

Global Bionic Optics Limited is a public company limited by shares. The Company is domiciled and incorporated in Australia. The financial report covers Global Bionic Optics Limited as an individual entity (Company) and includes consolidated financial statements and notes of controlled entities (Group).

The financial report is a general purpose financial report that has been prepared in accordance with Australian Accounting Standards, Australian Accounting Interpretations, other authoritative pronouncements of the Australian Accounting Standards Board and the Corporations Act 2001.

The Consolidated Entity Disclosure Statement has been prepared in accordance with the Corporations Act 2001.

Basis of preparation

The financial report is presented in Australian dollars and has been prepared on an accruals basis and is based on historical costs. Cost is based on the fair values of the consideration given in exchange for assets.

The following is a summary of the material accounting policies adopted by the Group in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated.

The financial report was approved by the Directors on 7th September 2026.

Going Concern

The Group incurred a net loss of \$1,068,368 (2025: \$1,270,122) for the financial year ended 30 June 2026 and, as at that date, the Group's total liabilities exceeded its total assets by \$9,198,023 (2025: \$8,010,021). The ability of the Group to continue as a going concern depends on the shareholders and directors' undertakings to provide continuing financial support.

The consolidated financial statements of the Group do not take into account any adjustments to the consolidated financial statements that would have to be made to reflect the situation that assets may need to be realised other than in the normal course of business and at amounts which could differ significantly from the amounts at which they are currently recorded in the Statement of Financial Position. In addition, the Group may have to provide for any further liabilities which may arise and to reclassify non current assets as current assets.

Estimates and judgments

The preparation of consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

NOTE 1: MATERIAL ACCOUNTING POLICY INFORMATION

Principles of consolidation

A controlled entity is an entity over which Global Bionic Optics Limited has the power to govern the financial and operating policies so as to obtain benefits from its activities. In assessing the power to govern, the existence and effect of holdings of actual and potential voting rights are considered. A list of controlled entities is contained in Note 23 to the consolidated financial statements.

As at reporting date, the assets and liabilities of all controlled entities have been incorporated into the consolidated financial statements as well as their results for the year then ended. Where controlled entities have entered / left the consolidated group during the year, their operating results have been included / excluded from the commencement of the financial year.

All intergroup balances and transactions between entities in the consolidated group, including any unrealised profits and losses, have been eliminated on consolidation. Accounting policies have been changed where necessary to ensure consistency with those adopted by the parent entity.

Financial Instruments

Non derivative financial instruments

Non derivative financial instruments comprise investments in debt securities, trade and other receivables, cash and cash equivalents and trade and other payables.

Non derivative financial instruments are initially recognised at fair value. Subsequent to initial recognition non derivative financial instruments are measured at fair value.

Cash & cash equivalents

Cash and cash equivalents comprise cash on hand and at call deposits with banks or financial institutions. Bank overdrafts that are repayable on demand are included as a component of cash and cash equivalents for the purpose of the Statement of Cashflows.

Trade & other receivables

Trade and other receivables are stated at their amortised cost less impairment losses.

Held to maturity investments

If the Company has the positive intent to hold debt securities to maturity, then they are classified as held to maturity. Held to maturity investments are measured at amortised cost using the effective interest rate method less any impairment losses.

Trade & other payables

Trade and other payables are stated at their cost.

Convertible Notes

Funds are loaned to the Company subject to a Convertible Note Agreement. Under the agreement, interest is payable at a prescribed rate over a set term before notes are repayable in cash or are converted at a prescribed value per share to ordinary shares in the Company.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

Plant and Equipment

Plant and equipment are carried at cost less, where applicable, any provisions for depreciation and impairment losses.

Carrying amounts

The carrying amount of plant and equipment is reviewed annually by directors to ensure there have been no impairment losses as a consequence of the carrying amounts exceeding the recoverable amount of the assets. The recoverable amount is assessed on the basis of expected net cash flows that will be received from the asset's employment and subsequent disposal.

A formal assessment of recoverable amounts is made when an impairment indicator is present.

Costs subsequent to the original purchase are either aggregated with the asset's original carrying amount or recognised as a separate asset, as appropriate, but only when it is probable that future economic benefits associated with the item will flow to the Group. All other repairs and maintenance costs are charged to the Statement of Comprehensive Income during the financial period in which they are incurred.

Gains and losses on disposal of an item of plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of plant and equipment and are recognised net within other income or other expenses in the profit or loss.

Depreciation

The depreciable amount of all plant & equipment is depreciated over their useful lives commencing from the time the asset is held ready for use. Rates and methods are reviewed annually for appropriateness.

The depreciation rates used for each class of depreciable assets are:

<i>Class of depreciable asset</i>	<i>Depreciation Rate</i>
Plant and equipment	3 – 7 years
Leasehold improvements	Over length of lease

Impairment

At each reporting date the Group reviews the carrying values of its financial assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the difference between the assets carrying amount and the estimated future cash flows discounted at the original effective interest rate is recognised through the profit and loss as an impairment loss.

The carrying value of the Group's non-financial assets are also reviewed at each reporting date to determine if there is an indication of impairment. If an indication exists then the assets recoverable amount, being the higher of its value in use and its fair value less costs to sell, is estimated. An impairment loss is recognised in the profit and loss if the carrying amount exceeds the recoverable amount.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

Leases

Leases are capitalised, recognising a right to use asset and a lease liability.

The right to use asset is initially recognised at the present value of the lease payments that are unpaid at the date of recognition. Lease payments are discounted at the interest rate implicit in the lease.

The lease liability is initially recognised at the carrying amount of the right to use asset increased by the interest on the lease liability.

Right of use assets are depreciated on a straight-line basis over their estimated useful lives.

Lease payments are allocated between the reduction of the lease liability and the lease interest expense for the period.

Employee benefits

Short-term benefits

Liabilities for employee benefits for wages, annual leave and sick leave arising from services rendered by employees to balance date represent present obligations. Employee benefits expected to be settled within one year have been measured at the amount expected to be paid when the liability is settled, plus related on-costs, such as workers' compensation insurance and payroll tax.

Long-term benefits

Other employee benefits payable later than one year have been measured at the present value of the estimated future cash outflows to be made for those benefits. The discount rate is the yield at reporting date on AA credit rated or government bonds that have maturity dates approximating the Group's obligations.

Superannuation

Contributions are made by the Group to employee superannuation funds and are charged as expenses when incurred.

Patents

Costs directly related to obtaining a patent are capitalised and amortised over a twenty year period, being the estimated useful life of the patent. The carrying value of patents is tested for impairment on an annual basis.

Inventories

Inventories are stated at the lower of cost and estimated selling price less costs to sell. Cost is determined using the First In First Out method. At each reporting date, inventories are assessed for impairment. If inventory is impaired the carrying amount is reduced to its selling price less costs to sell and the impairment loss is recognised immediately in the Statement of Comprehensive Income.

Income Tax

Income tax expense comprises current and deferred tax. Income tax is recognised in the Statement of Comprehensive Income except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

Income Tax (cont)

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the balance date, and any adjustments to tax payable in respect of previous years.

Deferred tax is provided using the balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date.

A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be utilised. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realised.

Comparative Figures

Where required by Accounting Standards comparative figures have been adjusted to conform with changes in presentation for the current financial year.

Revenue

Revenue from the sale of goods is recognised (net of returns, discounts and allowances) when control of the goods passes to the customers.

Licensing fees are recognised in accordance with contractually agreed terms with the customer.

Revenue from the rendering of a service is recognised upon the delivery of the service to the customers.

All revenue is stated net of the amount of goods and services tax (GST).

Finance income

Finance income comprises:

- interest revenue on funds invested. It is recognised on a proportional basis taking into account the interest rates applicable to the financial assets.
- interest expense and finance charges which are expensed in the period in which they are incurred.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

Goods and services tax

Revenues, expenses and assets are recognised net of the amount of goods and services tax (GST), except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO). In these circumstances the GST is recognised as part of the cost of the acquisition of the asset or as part of an item of expense.

Receivables and payables are stated with the amount of the GST included.

The net amount of GST recoverable from, or payable to, the ATO is included as a current asset or liability in the Statement of Financial Position. Cashflows are included in the Statement of Cashflows on a gross basis. The GST components of cashflows arising from investing and financing activities which are recoverable from, or payable to, the ATO are classified as operating cashflows.

Segment reporting

A segment is a distinguishable component of the Company that is engaged in either providing related products or services (business segment), or in providing products or services within a particular economic environment (geographical segment), which is subject to risks and rewards that are different from those of other segments.

Share issue costs

The costs related to the raising of equity are accounted for as a deduction from equity to the extent they are incremental costs directly attributable to the equity transaction that otherwise would have been avoided.

Share based payments

Share based compensation benefits are provided to employees and contractors.

The fair value of shares and options granted is recognised as a share based payments expense with a corresponding increase in equity. The fair value of options is measured at grant date and recognised over the period during which the employees or contractors become unconditionally entitled to the options.

New standards and interpretations not yet adopted

The Directors consider that new standards and interpretations currently issued but not yet applicable will not have a significant impact on the Group's financial report.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

	2026 \$	2025 \$
NOTE 2: REVENUE AND OTHER INCOME		
Revenue		
— Sales	318,225	76,529
	<u>318,225</u>	<u>76,529</u>
Other income		
— Sundry income	-	-
	<u>-</u>	<u>-</u>
TOTAL REVENUE	<u>318,225</u>	<u>76,529</u>

NOTE 3: NET FINANCE EXPENSE

Finance costs	339,340	290,241
	<u>339,340</u>	<u>290,241</u>

NOTE 4: OTHER EXPENSES

Audit fees	5,000	5,000
	<u>5,000</u>	<u>5,000</u>
Depreciation & amortisation expense		
— Depreciation	21,738	19,748
— Amortisation of patents	21,940	21,940
	<u>43,678</u>	<u>41,688</u>

NOTE 5: INCOME TAX

Recognised in the Statement of Comprehensive Income:

a. Income tax expense

Profit/(loss) before tax	(1,068,369)	(1,270,122)
Income tax using corporate tax rate 25%	(267,092)	(317,531)
Increase in income tax expense due to:		
— non-allowable items – share based payments	-	-
— non-allowable items – expenditure	-	-
Temporary differences and tax losses for which no deferred tax asset has been brought to account	267,092	317,531
Income tax expense/(benefit) on pre tax net profit	<u>-</u>	<u>-</u>
Total income tax expense in Statement of Comprehensive Income	<u>-</u>	<u>-</u>

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

	2026 \$	2025 \$
NOTE 6: RELATED PARTY TRANSACTIONS		
a. Key management personnel remuneration		
Short term salary benefits paid to all key management personnel of the Company by the Company and any related parties	12,915	13,098
Post employment superannuation benefits paid to all key management personnel of the Company by the Company and any related parties	1,584	1,495
	<u>14,499</u>	<u>14,593</u>

The names of key management personnel during the financial year are:

Luigi Ghirardello

John Florent

Stephen Diggle

b. Key Management Personnel Transactions

Entities related to Luigi Ghirardello and Stephen Diggle extended the term on loans of \$8,341,936 (2025: \$7,012,017) (convertible note agreements) during the year and agreed to the capitalisation of interest payable of \$320,844 (2025: \$269,693) on these loans.

Luigi Ghirardello lent the Company \$144,087 (2025: \$267,761) as part of a convertible note agreement. Refer Note 13 for details of the convertible notes.

A company related to Stephen Diggle, Vulpes Innovative Technologies Investment Company, lent the Company \$576,116 (2025: \$720,586) as part of a convertible note agreement. Refer Note 13 for details of the convertible notes.

John Florent was paid \$5,720 (2025: \$5,720) for the provision of taxation services.

	2026 \$	2025 \$
NOTE 7: CASH & CASH EQUIVALENTS		
Cash at bank	65,943	30,132
	<u>65,943</u>	<u>30,132</u>

Amounts are at call. The effective interest rate at 30 June 2026 on all accounts was <1% (2025: <1%)

Reconciliation of Cash

Cash at the end of the financial year as shown in the statement of cash flows is reconciled to items in the Statement of Financial Position as follows:

Cash	<u>65,943</u>	<u>30,132</u>
------	---------------	---------------

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

	2026 \$	2025 \$
NOTE 8: TRADE & OTHER RECEIVABLES		
CURRENT		
Trade debtor	-	5,100
GST Receivable	1,020	1,020
	<u>1,020</u>	<u>6,120</u>

None of the Groups receivables are past due (2025: Nil).

NOTE 9: OTHER ASSETS

CURRENT		
Prepayments & other deposits	26,248	2,121
	<u>26,248</u>	<u>2,121</u>

NOTE 10: PLANT AND EQUIPMENT

PLANT AND EQUIPMENT		
Plant and equipment - at cost	121,327	194,462
Accumulated depreciation	(115,733)	(165,794)
Total Plant and Equipment	<u>5,594</u>	<u>28,668</u>

b. Movements in Carrying Amounts

Movement in the carrying amounts for each class of plant and equipment between the beginning and the end of the current financial year

2026	1 July 2025	Adds	Disposals	Depreciation expense	30 June 2026
	\$	\$	\$	\$	\$
Plant & Equipment	28,668	-	(1,336)	(21,738)	5,594
	<u>28,668</u>	<u>-</u>	<u>(1,336)</u>	<u>(21,738)</u>	<u>5,594</u>
2025	1 July 2024	Adds	Disposals	Depreciation expense	30 June 2025
	\$	\$	\$	\$	\$
Plant & Equipment	36,774	11,642	-	(19,748)	28,668
	<u>36,774</u>	<u>11,642</u>	<u>-</u>	<u>(19,748)</u>	<u>28,668</u>

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

	2026	2025
	\$	\$
NOTE 11: INTANGIBLE ASSETS		
Patents at cost	438,801	438,801
Less accumulated amortisation	(403,242)	(381,302)
Written Down Value	<u>35,559</u>	<u>57,499</u>

Movement in Intangibles

Opening balance	57,499	79,439
Movement	(21,940)	(21,940)
Closing balance	<u>35,559</u>	<u>57,499</u>

Patents in relation to hash technology are pending.

NOTE 12: TRADE & OTHER PAYABLES

CURRENT

Other creditors	77,754	14,849
Accrued expenses	173,998	98,620
TOTAL CURRENT	<u>251,752</u>	<u>113,469</u>

Amounts are non-interest bearing. Creditors are expected to be paid within 30 days.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

	2026	2025
	\$	\$
NOTE 13: FINANCIAL LIABILITIES		
Convertible notes	9,080,635	8,021,092
	9,080,635	8,021,092

Convertible notes when issued are payable or are convertible at a defined point in time after date of issue.

The convertible note agreements set out conversion price/share interest payable. Profile of outstanding notes at 30 June 2026 and 30 June 2025 was:

2026	2025			
\$	\$	Maturity	Interest	Conversion Cost
711,822	602,911	July 2026	4%	Between 4c & 9c per share
691,404	576,876	August 2026	4%	Between 4c & 9c per share
586,745	480,990	September 2026	4%	Between 4c & 9c per share
786,012	671,483	October 2026	4%	Between 4c & 9c per share
729,674	615,499	November 2026	4%	Between 4c & 9c per share
1,956,227	1,799,823	December 2026	4%	Between 4c & 9c per share
532,317	462,042	January 2027	4%	Between 4c & 9c per share
565,051	488,279	February 2027	4%	Between 4c & 9c per share
725,346	643,203	March 2027	4%	Between 4c & 9c per share
581,574	512,234	April 2027	4%	Between 4c & 9c per share
710,298	682,978	May 2027	4%	Between 4c & 9c per share
504,165	484,774	June 2027	4%	Between 4c & 9c per share
9,080,635	8,021,092			

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 June 2026

NOTE 14: CONTRIBUTED EQUITY	2026	2025	2026	2025
	Qty	Qty	\$	\$
Fully paid ordinary shares	125,508,055	125,508,055	31,627,566	31,627,566
Total issued capital – fully paid shares	125,508,055	125,508,055	31,627,566	31,627,566

NOTE 15: CAPITAL AND LEASING COMMITMENTS

There were no capital or leasing commitments at 30 June 2026 (2025: NIL).

NOTE 16: CONTINGENT LIABILITIES AND CONTINGENT ASSETS

Contingent Liabilities

At the date of signing this report the directors are not aware of any contingent liabilities.

Contingent Assets

At the date of signing this report the directors are not aware of any contingent assets.

NOTE 17: STATEMENT OF OPERATIONS BY SEGMENTS

The Group operates in the imaging product industry in Australia and Singapore.

NOTE 18: EVENTS SUBSEQUENT TO REPORTING DATE

No matter or circumstance has arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in subsequent years.

NOTE 19: CASH FLOW INFORMATION	2026	2025
	\$	\$
a. Reconciliation of Cash Flow from Operations with Loss after Income Tax		
Loss after income tax	(1,068,368)	(1,270,122)
Non-cash flows in profit		
Amortisation of intangibles	21,940	21,940
Depreciation	21,738	19,748
Accrued interest on convertible notes	339,340	290,421
Changes in assets and liabilities		
Decrease/(increase) trade & other receivables	5,100	(5,100)
Decrease/(increase) other assets	(24,127)	(1,448)
Increase/(decrease) in sundry creditors	138,283	(30,869)
Cash flows from operations	<u>(566,094)</u>	<u>(975,430)</u>

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

NOTE 20: PARENT ENTITY DISCLOSURES	2026	2025
	\$	\$
Statement of Financial Position		
Current assets	9,321,496	8,611,806
Non-current assets	129,157	151,097
TOTAL ASSETS	<u>9,450,653</u>	<u>8,762,903</u>
 Current liabilities	 9,080,635	 8,021,092
TOTAL LIABILITIES	<u>9,080,635</u>	<u>8,021,092</u>
 EQUITY		
Issued Capital	31,627,566	31,627,566
Retained Losses	(31,257,548)	(30,885,755)
TOTAL EQUITY	<u>370,018</u>	<u>741,811</u>
 Statement of Comprehensive income		
Total Profit/(Loss)	(371,792)	(332,454)
Total Comprehensive Income/(Loss)	<u>(371,792)</u>	<u>(332,454)</u>

NOTE 21: FINANCIAL RISK MANAGEMENT

Credit Risk

Credit risk is the risk of financial loss to the Group if a customer fails to meet its obligations and arises principally from the Group's receivables from customers. The maximum exposure to credit risk, excluding the value of any collateral or other security, at balance date to recognised financial assets is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the Statement of Financial Position and the Notes to the Consolidated financial statements.

Trade and other receivables

The Group's exposure is influenced mainly by the individual characteristics of each customer. At balance date the main exposure to credit risk related to accounts receivable in respect of loans to directors. The Group has reviewed the outstanding trade and other receivables at year end and has assessed that no provision for impairment is required, as all amounts are considered to be collectable.

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

NOTE 21: FINANCIAL RISK MANAGEMENT con't

Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The company manages liquidity risk by monitoring forecast cash flows and ensuring that adequate cash reserves are maintained.

2026	<i>Carrying Amount</i>	<i>Contract Cashflows</i>	<i>6 months or less</i>	<i>6 – 12 months</i>	<i>1 – 2 years</i>	<i>2-5 years</i>	<i>More than 5 years</i>
<i>Non-derivative financial liabilities</i>	\$	\$	\$	\$	\$	\$	\$
Trade and other payables	251,752	251,752	251,752	-	-	-	-
Convertible Notes	9,080,635	9,080,635	5,461,884	3,618,751	-	-	-
2025	<i>Carrying Amount</i>	<i>Contract Cashflows</i>	<i>6 months or less</i>	<i>6 – 12 months</i>	<i>1 – 2 years</i>	<i>2-5 years</i>	<i>More than 5 years</i>
<i>Non-derivative financial liabilities</i>	\$	\$	\$	\$	\$	\$	\$
Trade and other payables	113,469	113,469	113,469	-	-	-	-
Convertible Notes	8,021,092	8,021,092	4,747,581	3,273,511	-	-	-

Currency risk

Currency risk is the risk that changes in exchange rates will affect the Group's receivables and payables denominated in foreign currency. The Group's sensitivity to these movements is considered immaterial for the purposes of this disclosure.

Fair Value

Unless otherwise stated carrying amounts disclosed on the Statement of Financial Position are the fair value of the financial assets and liabilities.

Interest rate risk

Interest rate risk is managed by regular market rate reviews. The Group has no exposure to interest rate risk as it holds no interest bearing liabilities.

The Group's exposure to interest rate risk, which is the risk that a financial instrument's value will fluctuate as a result of changes in market interest rates and the effective weighted average interest rates on classes of financial liabilities as follows:

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

NOTE 21: FINANCIAL RISK MANAGEMENT con't

2026	Weighted Average Effective Interest Rate	Floating Interest Rate	Fixed Interest Rate Maturing			Non Interest Bearing	Total Financial Assets/ Liabilities
			Within Year	1 to 5 Years	Over 5 Years		
	%	\$	\$	\$	\$	\$	\$
Financial Assets:							
Cash and cash equivalents	-	-	-	-	-	65,943	65,943
Receivables	-	-	-	-	-	1,020	1,020
Total Financial Assets		-	-	-	-	66,963	66,963
Plus Non Financial Assets:							
Other assets							26,248
Plant & equipment							5,594
Intangibles							35,559
Total Assets per Statement of Financial Position							134,364
Financial Liabilities:							
Convertible notes	4%	-	9,080,635	-	-	-	9,080,635
Trade and sundry payables	-	-	-	-	-	251,752	251,752
Total Financial Liabilities		-	9,080,635	-	-	251,752	9,332,387
Plus Non Financial Liabilities							
Other							-
Total Liabilities per Statement of Financial Position							9,332,387

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

NOTE 21: FINANCIAL RISK MANAGEMENT (con't)

2025	Weighted Average Effective Interest Rate	Floating Interest Rate	Fixed Interest Rate Maturing			Non Interest Bearing	Total Financial Assets/ Liabilities
	%	\$	Within Year	1 to 5 Years	Over 5 Years	\$	\$
Financial Assets:							
Cash and cash equivalents	-	-	-	-	-	30,132	30,132
Receivables	-	-	-	-	-	6,120	6,120
Total Financial Assets		-	-	-	-	36,252	36,252
Plus Non Financial Assets:							
Other Assets							2,121
Plant & equipment							28,668
Intangibles							57,499
Total Assets per Statement of Financial Position							124,540
Financial Liabilities:							
Convertible notes	3-4%	-	8,021,092	-	-	-	8,021,092
Trade and sundry payables	-	-	-	-	-	113,469	113,469
Total Financial Liabilities		-	8,021,092	-	-	113,469	8,134,561
Plus Non Financial Liabilities							
Other							-
Total Liabilities per Statement of Financial Position							8,134,561

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2026

NOTE 22: CAPITAL MANAGEMENT

Management controls the capital of the group in order to maintain a good debt to equity ratio, provide shareholders with adequate returns and ensure that the Group can fund its operations and continue as a going concern.

The Group's debt and capital includes ordinary share capital and financial liabilities, supported by financial assets.

There are no externally imposed capital requirements.

Management effectively manages the Group's capital by assessing the Group's financial risks and adjusting its capital structure in response to changes in these risks and in the market. These responses include management of debt levels, distributions to shareholders and share issues.

There have been no changes in the strategy adopted by management to control the capital of the Group since the prior year.

NOTE 23: CONTROLLED ENTITIES

<i>Controlled Entities Consolidated</i>	<i>Country of Incorporation</i>	<i>Percentage owned</i>		<i>Incorporated</i>
		2026	2025	
ZeroBiometrics Pte Ltd	Singapore	70	70	16 October 2014

NOTE 24: COMPANY DETAILS

The registered office and principal place of business of the Company is:

7986 Waterfall Way
Ebor NSW 2453

GLOBAL BIONIC OPTICS LIMITED
ABN 80 108 643 858
DIRECTORS' DECLARATION

In the opinion of the directors of Global Bionic Optics Limited

1. the consolidated financial statements and notes, as set out on pages 6 to 26 are in accordance with the Corporations Act 2001, including:
 - a. complying with Australian Accounting and the Corporations Regulations 2001; and
 - b. give a true and fair view of the financial position of the Group as at 30 June 2026 and its performance for the financial year ended on that date; and
 - c. the information contained in the attached Consolidated Entity Disclosure Statement is true and correct;
2. there are reasonable grounds to believe that the Group will be able to pay their debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

Director



Luigi Ghirardello

Director



John Florent

Dated this 7th day of September 2026

INDEPENDENT AUDIT REPORT TO THE MEMBERS OF GLOBAL BIONIC OPTICS LIMITED

Report on the Audit of the Financial Report

Opinion

We have audited the consolidated financial report of Global Bionic Optics Limited. (the Group), which comprises the Statement of Financial Position as at 30 June 2026, the Statement of Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and Notes to the Consolidated financial statements, including material accounting policy information, the Consolidated Entity Disclosure Statement, and the Directors' Declaration.

In our opinion, the accompanying consolidated financial report of Global Bionic Optics Limited, is in accordance with the Corporations Act 2001, including:

- (a) giving a true and fair view of the Group's financial position as at 30 June 2026 and of its financial performance for the year then ended; and
- (b) complying with Australian Accounting Standards and the Corporations Regulations 2001.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code. We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 in the financial report, which indicates that the Group incurred a net loss of \$1,068,368 during the year ended 30 June 2026 and, as of that date, the Group's cashflow from operations for the year ended 30 June 2026 was a net outflow of \$566,094. The consolidated financial statements have been prepared on a going concern basis as directors believe the development of the technology will result in successful sale of the technology in future years. The Group are reliant on the ongoing funding being provided by directors and their related entities, the subsequent conversion of these funds to shares and capital raisings.

At the date of this report, if this funding were not to continue, the Group's assets would need to be restated to a realisable value as the Group would not be a going concern.

Our opinion is not modified in respect of this matter.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2026, but does

INDEPENDENT AUDIT REPORT TO THE MEMBERS OF GLOBAL BIONIC OPTICS LIMITED

not include the financial report and our auditor's report thereon. Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of:

- the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001; and
- the consolidated entity disclosure statement that is true and correct in accordance with the Corporations Act 2001; and

for such internal control as the directors determine are necessary to enable the preparation of:

- the financial report, other than the consolidated entity disclosure statement, that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- the consolidated entity disclosure statement that is true and correct and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the consolidated financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at: <http://www.auasb.gov.au/Home.aspx>. This description forms part of our auditor's report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our

**INDEPENDENT AUDIT REPORT
TO THE MEMBERS OF GLOBAL BIONIC OPTICS LIMITED**


opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
 - Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion.
- Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial report, including the disclosures, and whether the consolidated financial report represents the underlying transactions and events in a manner that achieves fair presentation. We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial report of the current period and are therefore the key audit matters.

We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Essential Assurance Services Pty Ltd
ABN 51 119 802 229
Authorised Audit Company #305383



Signed by: Rhonda Futterleib

Address: 22 Pulteney Street, Taree, NSW, 2430

Dated this 8th September 2026

Liability limited by a scheme approved under Professional Standards Legislation